Breast cancer study: does adding trastuzumab to Pre-Surgery chemo improve outcomes?
NCT ID NCT01750073
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial studied 92 women with early-stage breast cancer to see how well chemotherapy (paclitaxel and cyclophosphamide) with or without trastuzumab works before surgery. The main goals were to check side effects and see if the tumor disappears completely by the time of surgery. The study included patients with different types of breast cancer, including HER2-positive and HER2-negative.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
paclitaxel, cyclophosphamide, and trastuzumab
What this could lead to
If successful, this could show that adding trastuzumab to chemotherapy before surgery helps shrink tumors more effectively in HER2-positive breast cancer patients.
What could go wrong
This is a small, completed phase II trial, so results are preliminary. The approach may not work for all breast cancer types, and chemotherapy carries risks like infection and heart damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHI Health Saint Francis
Grand Island, Nebraska, 68803, United States
-
Nebraska Medicine-Bellevue
Bellevue, Nebraska, 68123, United States
-
Nebraska Medicine-Village Pointe Cancer Center
Omaha, Nebraska, 68118, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States